Navitoclax (ABT-263)

For research use only. Not for use in humans.

目录号：S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3285.53	现货
5mg	RMB 975.71	现货
10mg	RMB 1631.61	现货
25mg	RMB 3016.58	现货
100mg	RMB 7950.36	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Navitoclax (ABT-263)发表文献158篇：

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )
Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )
Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )
Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )
Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )
J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )
Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

靶点

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，K_i分别为0.5, 1和1 nM。^[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M2jFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfQTWM2OD1yLkCwOlY6KM7:TR?=	MlPtV2FPT0WU
MV-4-11	M1;kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzJTWM2OD1yLkCxOVg3KM7:TR?=	NUnvRmcyW0GQR1XS
NKM-1	M{LrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;HPGlEPTB;MD6wNVY6QSEQvF2=	NGLC[4FUSU6JRWK=
ML-2	MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjqeWFbUUN3ME2wMlAyQTh\|IN88US=>	NGnxRo1USU6JRWK=
BV-173	NF7S[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMEKzNVQh\|ryP	NGrBPFdUSU6JRWK=
RS4-11	NGPod4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17udGlEPTB;MD6wNlU5PyEQvF2=	M{jOZ3NCVkeHUh?=
HL-60	NF;FdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzybFlKSzVyPUCuNFI6ODhizszN	MkTtV2FPT0WU
KY821	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3zWXZKSzVyPUCuNFI6PzVizszN	M3ezZnNCVkeHUh?=
ECC10	NWq4RWM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm4XFBKSzVyPUCuNFM4QTJizszN	NED3S5pUSU6JRWK=
NCI-H720	NX:1UmtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlryTWM2OD1yLkC0NFEyKM7:TR?=	MUnTRW5ITVJ?
QIMR-WIL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3SxWmlEPTB;MD6wOFI5PyEQvF2=	NWf2THcxW0GQR1XS
KG-1	NIXuNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr1So5wUUN3ME2wMlA1PDh4IN88US=>	M1LVSXNCVkeHUh?=
TGW	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW3fmNSUUN3ME2wMlA1PjN\|IN88US=>	MnzsV2FPT0WU
ATN-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPyTWM2OD1yLkC0O\|M{KM7:TR?=	MmG4V2FPT0WU
RH-18	NVjZ[GJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTzTWM2OD1yLkC2NFQ5KM7:TR?=	M{HxfHNCVkeHUh?=
EW-18	M{Hx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGC0TnJKSzVyPUCuNFY5PDFizszN	M1rRU3NCVkeHUh?=
NB17	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Z[\|h{UUN3ME2wMlA4OTJ2IN88US=>	MWLTRW5ITVJ?
SK-NEP-1	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVSxUIFJUUN3ME2wMlA4OjF\|IN88US=>	M4n4VXNCVkeHUh?=
P12-ICHIKAWA	NUTEfooyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfQeHdVUUN3ME2wMlA4Pzd6IN88US=>	NW\tXIZWW0GQR1XS
KARPAS-45	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMEe4NVUh\|ryP	M2jDRnNCVkeHUh?=
EW-3	M2f4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjJVWNKSzVyPUCuNFgxPTNizszN	M3\yR3NCVkeHUh?=
NB13	M3XEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonBTWM2OD1yLkC4NlA{KM7:TR?=	MmC0V2FPT0WU
NCI-H209	NHfzPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrRcXhKSzVyPUCuNFg4ODRizszN	MmflV2FPT0WU
NCI-H1092	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMUCyO\|Uh\|ryP	NHzpV3NUSU6JRWK=
NH-12	NVLXbFV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X4emlEPTB;MD6xNFc1PCEQvF2=	M4\DNnNCVkeHUh?=
697	M4HLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XEdmlEPTB;MD6xNFg{QSEQvF2=	MY\TRW5ITVJ?
KE-37	NFqyUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHwTWM2OD1yLkGxN\|ch\|ryP	M1;yfXNCVkeHUh?=
MOLT-4	NYDlPZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHKfJl6UUN3ME2wMlE2OTZ7IN88US=>	M2DDNHNCVkeHUh?=
CHP-134	M2HG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXKPJJKSzVyPUCuNVY{ODZizszN	NFLMW4VUSU6JRWK=
D-283MED	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMUe2PFYh\|ryP	NIX6dFFUSU6JRWK=
LU-135	NEfscGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMUi1OVIh\|ryP	MojDV2FPT0WU
LU-134-A	NWPEOI42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELUW3RKSzVyPUCuNVg3PzFizszN	M3nqfnNCVkeHUh?=
EM-2	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HLeGlEPTB;MD6xPVkyQCEQvF2=	MXjTRW5ITVJ?
LU-139	NELjSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHNRoRUUUN3ME2wMlIxPDl6IN88US=>	NWP1Zpk1W0GQR1XS
ALL-PO	M2jocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnne\|ZtUUN3ME2wMlIyQTh6IN88US=>	M{PrXnNCVkeHUh?=
NB12	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULTfoRWUUN3ME2wMlI{OTF3IN88US=>	NU\xVW4{W0GQR1XS
KP-N-YN	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3RXJJKSzVyPUCuNlM2PzNizszN	NHqzU\|RUSU6JRWK=
BEN	NUjRPFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED6RlVKSzVyPUCuNlM6PjhizszN	NFL6Z5RUSU6JRWK=
HCC1569	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[5W4tKSzVyPUCuNlUyODZizszN	NVvzRZJkW0GQR1XS
HuO9	NEjadmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPVTWM2OD1yLkK2O\|E2KM7:TR?=	MYrTRW5ITVJ?
WM-115	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEm5d2RKSzVyPUCuNlc4OzhizszN	M{LPcHNCVkeHUh?=
CCRF-CEM	M3XIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwM{O1Nlkh\|ryP	NVnZbXFoW0GQR1XS
IST-SL1	NUPjOo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjkNG9XUUN3ME2wMlM2OzR\|IN88US=>	M3LxOHNCVkeHUh?=
BE-13	NHizZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLFc4VKSzVyPUCuN\|Y1PTlizszN	MoTBV2FPT0WU
COR-L88	NGe1PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\WTWM2OD1yLkO2OVQh\|ryP	M2i1WHNCVkeHUh?=
DOHH-2	M2TUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHPTWM2OD1yLkSxNFI{KM7:TR?=	NIHCTm9USU6JRWK=
A704	NYnGZo1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXOfId6UUN3ME2wMlQzPjdizszN	M2nSVnNCVkeHUh?=
KNS-81-FD	NFfIc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwNESwNVch\|ryP	Mnj1V2FPT0WU
RPMI-8226	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLySHdDUUN3ME2wMlQ2PjV{IN88US=>	MUDTRW5ITVJ?
TGBC24TKB	NXXCS2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwNEW3O\|gh\|ryP	NWnTNoc2W0GQR1XS
NCI-H1304	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTWNoM6UUN3ME2wMlQ3OTV5IN88US=>	M2fZ[XNCVkeHUh?=
MOLT-13	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLHTWM2OD1yLkS2OlE{KM7:TR?=	MVLTRW5ITVJ?
EW-22	NGPYUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfITWM2OD1yLkS2OlcyKM7:TR?=	NVXkbVhTW0GQR1XS
MS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfvSWFKSzVyPUCuOFY6OzNizszN	NYDtfpNjW0GQR1XS
RMG-I	M1\0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwNEm0OlQh\|ryP	MnnMV2FPT0WU
NTERA-S-cl-D1	M3TNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGizS\|BKSzVyPUCuOVAxOTlizszN	M2\JUHNCVkeHUh?=
NCI-H1048	NWG4doc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwNUC5OVMh\|ryP	MnPtV2FPT0WU
SW1417	NUTDdZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{n2XmlEPTB;MD61OVQ{QCEQvF2=	MoTjV2FPT0WU
DB	NYPk[oFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvHb2ZKSzVyPUCuOVcxQCEQvF2=	Mkn0V2FPT0WU
MEG-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[4OGlEPTB;MD61PFMzKM7:TR?=	M4nsPHNCVkeHUh?=
EW-13	M1[5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfGOWZKSzVyPUCuOVg{PDFizszN	M3nDdXNCVkeHUh?=
LAMA-84	NWPNe4JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Ps[2lEPTB;MD61PVIxPyEQvF2=	NUTseIxEW0GQR1XS
J-RT3-T3-5	M{Ph[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jRV2lEPTB;MD62NFgxQCEQvF2=	NV:xcpJMW0GQR1XS
MOLT-16	NXnhVZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHVPW5KSzVyPUCuOlUzPjRizszN	M4rxXXNCVkeHUh?=
DU-4475	M2DJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGezSJdKSzVyPUCuOlU1OjdizszN	NWHUUVl7W0GQR1XS
HAL-01	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{CzdmlEPTB;MD63NlU1QSEQvF2=	NYDKUnpRW0GQR1XS
RD	NXOxcVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwN{W4PVkh\|ryP	M2PpRnNCVkeHUh?=
OAW-28	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3vT3lKSzVyPUCuO\|g{PyEQvF2=	MkfxV2FPT0WU
HCC38	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfCdYdKSzVyPUCuPFAyQSEQvF2=	Ml3DV2FPT0WU
NMC-G1	M4m4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnhc\|FpUUN3ME2wMlgyOTJzIN88US=>	NGXHcHhUSU6JRWK=
EW-16	NVnwcG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLaTWM2OD1yLkixN\|I5KM7:TR?=	NUDnZWZsW0GQR1XS
DU-145	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\HTWM2OD1yLki5PVI{KM7:TR?=	NXrQcWhqW0GQR1XS
HPAF-II	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwOUK2Nlgh\|ryP	NU[5SGk5W0GQR1XS
A427	MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\G[GlEPTB;MD65N\|AzOiEQvF2=	MUXTRW5ITVJ?
PA-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFm4bZJKSzVyPUCuPVU3PDJizszN	NHjSTGZUSU6JRWK=
OAW-42	NILIXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr2fnpKSzVyPUCuPVYyPDZizszN	NXHOe3VyW0GQR1XS
L-428	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTFwMEGyOUDPxE1?	NHzB[2ZUSU6JRWK=
COLO-824	M1TJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnMb5lKSzVyPUGuNFE4ODhizszN	MUHTRW5ITVJ?
P30-OHK	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTZW\|N7UUN3ME2xMlA1Pjh6IN88US=>	NYPneJR5W0GQR1XS
NCI-H2170	NUPBNYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTFwME[yN{DPxE1?	M2DZd3NCVkeHUh?=
HCC2998	NVvkSXlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz3RWRKSzVyPUGuNFcyOzVizszN	NYPOeVV6W0GQR1XS
NB14	M2fYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfnTWxKSzVyPUGuNVM4PDhizszN	Mlm4V2FPT0WU
TGBC1TKB	M4ez[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDscIY4UUN3ME2xMlE1OTV{IN88US=>	Mn;FV2FPT0WU
KP-N-YS	M3\4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:xNGlEPTB;MT6xOlI{PiEQvF2=	NHvneY9USU6JRWK=
CAL-120	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fyZmlEPTB;MT6xOlQzQSEQvF2=	NGXJZ4hUSU6JRWK=
SBC-1	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\jXFRKSzVyPUGuNVkxPTNizszN	M1fJ[nNCVkeHUh?=
C32	NFOwfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTFwMUmwPFgh\|ryP	MknrV2FPT0WU
HCC2157	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTFwMUm0PVQh\|ryP	NUnOVXVMW0GQR1XS
COLO-792	NHm0ZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS0VY5ZUUN3ME2xMlIxODdzIN88US=>	NYj4WY4zW0GQR1XS
ES7	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\lTmhKSzVyPUGuNlc6PTFizszN	MWLTRW5ITVJ?
HEL	NYTEOIpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFmyTHpKSzVyPUGuN\|ExOjlizszN	Mlq1V2FPT0WU
ES4	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTFwM{S5PVgh\|ryP	NV3rTVc6W0GQR1XS
NCI-SNU-1	NWL2fG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTFwM{[1OVUh\|ryP	M2LMe3NCVkeHUh?=
MDA-MB-415	NHTP[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwM{i4OUDPxE1?	NGeyc4lUSU6JRWK=
NCI-H2342	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjjd4ZEUUN3ME2xMlQxOjZ7IN88US=>	M1G0dnNCVkeHUh?=
NB69	NIDQRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHT4dYhKSzVyPUGuOFYzPzFizszN	MnPwV2FPT0WU
D-247MG	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTWTWM2OD1zLkWxNVIzKM7:TR?=	MnriV2FPT0WU
SCC-4	NWjEOppYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF76Sm1KSzVyPUGuOVk5QDdizszN	M{PjUnNCVkeHUh?=
HuH-7	NX3Sb2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrzTWM2OD1zLk[3Nlk{KM7:TR?=	NWCwXYFuW0GQR1XS
A388	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH6TWM2OD1zLk[4O\|I1KM7:TR?=	Mkn2V2FPT0WU
Calu-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwN{C2PVch\|ryP	NYfWU5ZRW0GQR1XS
NCI-H1648	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1r5WWlEPTB;MT63NVQyQCEQvF2=	NF:5dG5USU6JRWK=
NCI-H2052	NGfzZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPZTWM2OD1zLkeyNlAyKM7:TR?=	MVXTRW5ITVJ?
Ramos-2G6-4C10	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrBRmhKSzVyPUGuO\|M3PTZizszN	NEO3V41USU6JRWK=
DEL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDZdWJKSzVyPUGuO\|Q3QTJizszN	MoTQV2FPT0WU
SNU-423	M4XrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjsOlBKSzVyPUGuO\|gyPTdizszN	MknrV2FPT0WU
COR-L23	NWWwZ4tMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPIfnVKSzVyPUGuO\|k5PzRizszN	Mni4V2FPT0WU
OMC-1	NWrXW4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HNcmlEPTB;MT64OlAyPiEQvF2=	MofwV2FPT0WU
EW-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTFwOUW2OVch\|ryP	NF3ldoZUSU6JRWK=
HSC-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTMSWlCUUN3ME2xMlk3OzZ3IN88US=>	NIHIVVZUSU6JRWK=
MLMA	NU\LVZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfLVYJKSzVyPUGuPVY3PzdizszN	NH3qb3JUSU6JRWK=
RCM-1	NXLQbmFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C0WmlEPTB;Mj6wNFM6QSEQvF2=	NWnLPWF3W0GQR1XS
MFE-280	M1yyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTJwMEK4OFgh\|ryP	M3jQc3NCVkeHUh?=
ES8	NEnDSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTJwMkW0O\|Eh\|ryP	NHHMRpJUSU6JRWK=
TE-11	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTVUY1TUUN3ME2yMlI6PDd\|IN88US=>	Mo[5V2FPT0WU
HuO-3N1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILkPW9KSzVyPUKuOFg4QCEQvF2=	NWDZfFFFW0GQR1XS
MHH-NB-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LnfGlEPTB;Mj61NVE2QCEQvF2=	NFLHbW9USU6JRWK=
TGBC11TKB	NV3abVZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3NZ4hKSzVyPUKuOVc3QDFizszN	Ml36V2FPT0WU
HOP-92	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7lSlRKSzVyPUKuOVg4PDNizszN	NX3KdodUW0GQR1XS
IGR-1	NFXVfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDVTWM2OD1{Lk[yNFM2KM7:TR?=	NYjzXGVTW0GQR1XS
GOTO	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjlUHNKSzVyPUKuOlU{PzdizszN	MmHtV2FPT0WU
NCI-H1650	M3npNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\KNIZ{UUN3ME2yMlczOjF3IN88US=>	MmeyV2FPT0WU
NCI-H1581	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJwN{m2PFEh\|ryP	MlPxV2FPT0WU
NCI-H2405	NVPqNXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTJwOEK3PFIh\|ryP	NFLxZohUSU6JRWK=
U-118-MG	NGC4d2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHadIQ3UUN3ME2yMlk3PDlzIN88US=>	M13i[XNCVkeHUh?=
DoTc2-4510	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Ps[WlEPTB;Mz6wNVQyPyEQvF2=	MkDXV2FPT0WU
NCI-H596	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfSTY9rUUN3ME2zMlA1QTl5IN88US=>	NXjZNphVW0GQR1XS
MPP-89	MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHLcFBnUUN3ME2zMlA2PjZ4IN88US=>	NV7sWnV7W0GQR1XS
GCIY	NUXtR2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf1TWM2OD1\|LkKwOFkyKM7:TR?=	MXfTRW5ITVJ?
SW626	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmS0TWM2OD1\|LkK0OVQ{KM7:TR?=	NFzCd3pUSU6JRWK=
OCI-AML2	NXfyVpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NICwWpFKSzVyPUOuN\|EzPzJizszN	MlPwV2FPT0WU
NBsusSR	M1rRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzjTWM2OD1\|LkO0PVM5KM7:TR?=	M1[zOHNCVkeHUh?=
AN3-CA	NXexT5pJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGf3bFdKSzVyPUOuOFQzOzhizszN	NYTnTJppW0GQR1XS
EFM-19	Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\4Rm5KSzVyPUOuOFg{OzlizszN	NEfN[ZpUSU6JRWK=
RVH-421	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\HNWlEPTB;Mz61Olg4PyEQvF2=	NGTGUVVUSU6JRWK=
5637	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET2dXNKSzVyPUOuOlEyODNizszN	M1H4WnNCVkeHUh?=
PANC-08-13	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PEdGlEPTB;Mz62N\|Q4OiEQvF2=	M3nyVHNCVkeHUh?=
H9	MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDBR3JxUUN3ME2zMlY4OTR2IN88US=>	NFzCd3dUSU6JRWK=
KARPAS-299	NF\Y[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTNwNkezOlEh\|ryP	MYTTRW5ITVJ?
TE-5	M1LOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvhbZpKSzVyPUOuO\|A4ODlizszN	NYTPUGVtW0GQR1XS
NOS-1	M4mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkf2TWM2OD1\|Lke5PFM1KM7:TR?=	MU\TRW5ITVJ?
HH	NILoO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHofoZvUUN3ME2zMlg{QDZ6IN88US=>	NUfBVGF1W0GQR1XS
769-P	NVXaZolxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEn0VItKSzVyPUOuPFk2OSEQvF2=	MWHTRW5ITVJ?
CHP-212	M2LCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTNwOUK1OFkh\|ryP	MX;TRW5ITVJ?
NCI-H82	NYn2PGZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHINGRtUUN3ME2zMlk2QTN4IN88US=>	MUXTRW5ITVJ?
Mo-T	NWL4SlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MluwTWM2OD12LkC0N\|EzKM7:TR?=	NWDheJB{W0GQR1XS
BB65-RCC	NILxT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTRwMESzPVkh\|ryP	Mlm1V2FPT0WU
SW1990	NYT3RpByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\RWmlEPTB;ND6wOVkxQCEQvF2=	NXzXSZhEW0GQR1XS
LK-2	NEfBW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTRwMUGyPVMh\|ryP	MVfTRW5ITVJ?
ES5	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjLcpN[UUN3ME20MlE{QTh3IN88US=>	MlzGV2FPT0WU
JVM-3	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTRwMUiyNlIh\|ryP	M2jCT3NCVkeHUh?=
RPMI-7951	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfPTWM2OD12LkKyOFE{KM7:TR?=	M3O1e3NCVkeHUh?=
Calu-6	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTrS\|diUUN3ME20MlI4QDhzIN88US=>	M{HqZXNCVkeHUh?=
LC-2-ad	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHK2VGVKSzVyPUSuNlk2PjhizszN	MoflV2FPT0WU
SW954	M4H6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LvS2lEPTB;ND6yPVY3KM7:TR?=	M4HBT3NCVkeHUh?=
H-EMC-SS	M4HVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorUTWM2OD12LkOxPFMyKM7:TR?=	NXPNNnhjW0GQR1XS
ES3	M1P6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTRwM{W0OFEh\|ryP	NGPzW\|RUSU6JRWK=
no-11	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XoSGlEPTB;ND6zOVU2PCEQvF2=	NEP5OmNUSU6JRWK=
LAN-6	M1Gzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2KyOGlEPTB;ND60OVE5QSEQvF2=	MWnTRW5ITVJ?
FTC-133	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTRwNUO5OUDPxE1?	NGjYTm5USU6JRWK=
8505C	NFTJO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTTb3B6UUN3ME20MlU1OjNizszN	M{DvNXNCVkeHUh?=
SW620	NEi1T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\5boJKSzVyPUSuOVcxPTdizszN	M1WxNXNCVkeHUh?=
BCPAP	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELuPZdKSzVyPUSuOlM1QDFizszN	NVrSPHJoW0GQR1XS
SK-LU-1	NILWPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3pTWM2OD12Lk[2NFg6KM7:TR?=	NG\1O4dUSU6JRWK=
NCI-H1623	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTRwN{CyNlgh\|ryP	M1vCU3NCVkeHUh?=
C2BBe1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTRwN{SwNFgh\|ryP	NXPPc5JpW0GQR1XS
GP5d	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TkeGlEPTB;ND63PFM5QCEQvF2=	MX\TRW5ITVJ?
NB6	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3joR2lEPTB;ND64OlIxPCEQvF2=	NFXnc2NUSU6JRWK=
MDA-MB-157	NXf1UmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zTZWlEPTB;ND64PFc3KM7:TR?=	MXzTRW5ITVJ?
UMC-11	NGjOfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\JWGlEPTB;ND64PFk3PCEQvF2=	MknQV2FPT0WU
HCC1419	M4izRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRwOUCwOlMh\|ryP	NU\Jb4xxW0GQR1XS
NCI-H2029	NVj2[YJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3ZfY9wUUN3ME20Mlk1OTh3IN88US=>	MoXrV2FPT0WU
LXF-289	NVm1SmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnITWM2OD13LkCzO\|E6KM7:TR?=	NX;ZOlFGW0GQR1XS
KINGS-1	MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTVwMEe3OFQh\|ryP	M3[4bXNCVkeHUh?=
HD-MY-Z	M3PHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1qxfGlEPTB;NT6yN\|k3QSEQvF2=	Mlf1V2FPT0WU
ESS-1	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHNTWM2OD13LkK1OVk4KM7:TR?=	NYT1fpZzW0GQR1XS
GI-1	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfEWmY5UUN3ME21MlI4QTJ4IN88US=>	M{\VWXNCVkeHUh?=
RPMI-2650	M2C1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDTTWM2OD13LkO2NVYh\|ryP	NGjGdmpUSU6JRWK=
IA-LM	NWexTowyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLISW5{UUN3ME21MlM6QDdzIN88US=>	MULTRW5ITVJ?
KP-4	NIOyUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT1TWM2OD13LkS2N\|M1KM7:TR?=	NH7mV4NUSU6JRWK=
G-402	NFvBOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHuSI5KSzVyPUWuOVE5PjVizszN	M1e1XXNCVkeHUh?=
OS-RC-2	NGm1U3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PnUGlEPTB;NT61NlYxPCEQvF2=	NUC2dIhxW0GQR1XS
NCI-H1155	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPM[4lbUUN3ME21MlU1QTV3IN88US=>	MV3TRW5ITVJ?
OE19	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HzbmlEPTB;NT62PFYzPCEQvF2=	M2TOcHNCVkeHUh?=
U-2-OS	NEft[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojPTWM2OD13Lki5NFE{KM7:TR?=	M{f6PHNCVkeHUh?=
SCC-15	NYXI[mQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjDTVhKSzVyPUWuPVM3PjJizszN	MWHTRW5ITVJ?
NCI-H630	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlK5TWM2OD13Lkm5OFA1KM7:TR?=	MXnTRW5ITVJ?
PFSK-1	NUjjU5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\ZTWM2OD14LkC1NlU6KM7:TR?=	MmPQV2FPT0WU
NCI-H1770	NIPa[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHETWM2OD14LkKwPFc1KM7:TR?=	NVHvSJpMW0GQR1XS
SK-MEL-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPCcolKSzVyPU[uOFI6OTVizszN	M2LLNXNCVkeHUh?=
LB1047-RCC	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPrZmNKSzVyPU[uOFc3OjVizszN	NULjNZhVW0GQR1XS
NCI-H446	NHfTfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D0cWlEPTB;Nj62NlkzPSEQvF2=	NXnNeWd[W0GQR1XS
SW780	NIfITVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWCwfG46UUN3ME22MlcxOTh3IN88US=>	M4TEfnNCVkeHUh?=
NEC8	NWXSZlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLDTWM2OD14Lke2OlMh\|ryP	MVvTRW5ITVJ?
NOMO-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTZwN{ixNVEh\|ryP	M{e5bHNCVkeHUh?=
COLO-668	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\yVmVKSzVyPU[uPFQ{QDdizszN	NVfQ[GVuW0GQR1XS
MC116	NHPT[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rDRmlEPTB;Nj65N\|g6PyEQvF2=	MlzLV2FPT0WU
HCC1937	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jwb2lEPTB;Nj65PVI2OSEQvF2=	MkW1V2FPT0WU
NCI-N87	NXXvWZZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XMUGlEPTB;Nz6xPVI6OyEQvF2=	Mo\QV2FPT0WU
COLO-320-HSR	NHz3OZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3G3RmlEPTB;Nz6yNlc{QCEQvF2=	MUXTRW5ITVJ?
HCC1806	M1njemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;1TWM2OD15LkK2NFQ1KM7:TR?=	M1HsRXNCVkeHUh?=
OVCAR-3	NE\CTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTdwM{OwN\|gh\|ryP	M4fZ[XNCVkeHUh?=
NUGC-3	NGf3PIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfZZ5VrUUN3ME23MlM6Pjl2IN88US=>	NFT6OFhUSU6JRWK=
SW1783	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TU[2lEPTB;Nz60N\|E4PSEQvF2=	MYfTRW5ITVJ?
GCT	NHi5cGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;6cWlEPTB;Nz61OlkxPiEQvF2=	M4rGVHNCVkeHUh?=
NCI-H2126	M3zWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTdwN{O2NlUh\|ryP	M{HrcHNCVkeHUh?=
MEL-HO	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTXZoJKSzVyPUeuO\|cxPTRizszN	MkDNV2FPT0WU
CAPAN-1	M1PKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTdwN{ezOVch\|ryP	M3fzRnNCVkeHUh?=
SW756	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjXRWFKSzVyPUeuO\|g{OzNizszN	MYPTRW5ITVJ?
SKG-IIIa	NFTZdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zRbmlEPTB;Nz64NVg6OiEQvF2=	M4HONXNCVkeHUh?=
HCE-T	NWTVRpprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTdwOEe3PFMh\|ryP	NYHFfXdIW0GQR1XS
Ca-Ski	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rIXGlEPTB;Nz65PVM5OyEQvF2=	M4XxPHNCVkeHUh?=
COLO-684	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPUbmd7UUN3ME24MlAyQDF6IN88US=>	MknGV2FPT0WU
KYSE-70	NXy0O44xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEn1bWRKSzVyPUiuNFc4OjlizszN	M4qxNXNCVkeHUh?=
TI-73	MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;JWGlEPTB;OD6yOVg2OSEQvF2=	NVjKd\|ZMW0GQR1XS
BT-20	NXnLOHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRThwMk[wOVIh\|ryP	M2SzfnNCVkeHUh?=
MHH-ES-1	M1OzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\Ne3FUUUN3ME24MlUyQDN2IN88US=>	NGDifXBUSU6JRWK=
TE-12	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRThwNUm5N\|Eh\|ryP	M4fNd3NCVkeHUh?=
YH-13	M1XKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjvfnA5UUN3ME24MlYyODB6IN88US=>	Mn;kV2FPT0WU
SF126	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvQd\|lkUUN3ME24Mlg{QDZ3IN88US=>	M2XyWXNCVkeHUh?=
J82	NHT3bWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRThwOUCwN\|gh\|ryP	MXLTRW5ITVJ?
RCC10RGB	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRThwOUm1OlEh\|ryP	M3mzZXNCVkeHUh?=
SK-UT-1	M{DPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvHTWM2OD17LkC0PVQ2KM7:TR?=	NWrrS2R[W0GQR1XS
LB2241-RCC	NV7TW2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrZTWM2OD17LkG5NVM4KM7:TR?=	NWDYUmhXW0GQR1XS
LB996-RCC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljuTWM2OD17LkG5PFkh\|ryP	NGP5flZUSU6JRWK=
EPLC-272H	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T5NWlEPTB;OT6zO\|Y2PyEQvF2=	NFzac\|NUSU6JRWK=
CTV-1	M4DzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17lNGlEPTB;OT61OlU{OiEQvF2=	NWi2XYNVW0GQR1XS
HSC-2	M1PFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnMT3RWUUN3ME25MlU4PTVizszN	M1rFcXNCVkeHUh?=
SK-MEL-28	NIfFeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTlwNkG4PVMh\|ryP	NXTEXXZiW0GQR1XS
MMAC-SF	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLNTWM2OD17Lk[4O\|Uh\|ryP	M4rucXNCVkeHUh?=
CP50-MEL-B	NXXwe2t{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXq2SnVqUUN3ME25Mlc2Pzh{IN88US=>	NYL5SnJ[W0GQR1XS
HT-1080	NGmwZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLY[4RKSzVyPUmuO\|c4OzlizszN	MXfTRW5ITVJ?
HEC-1	NX\5[Y5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7ocYhKSzVyPUGwMlM{PTJizszN	MlHHV2FPT0WU
AGS	NH;TeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHTTWM2OD1zMD6zO\|Qh\|ryP	MnTkV2FPT0WU
GAMG	NFXR[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;2d4hKSzVyPUGwMlUyPjJizszN	MofvV2FPT0WU
SW48	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjybG9tUUN3ME2xNE42OTh7IN88US=>	NEnzO5ZUSU6JRWK=
U031	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnSwTWM2OD1zMD61PVA5KM7:TR?=	NE\qTolUSU6JRWK=
OVCAR-5	NGS4ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vRUWlEPTB;MUCuOlQzQSEQvF2=	MWTTRW5ITVJ?
SF295	NV3zSlZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfhSG9KSzVyPUGwMlY4ODRizszN	MWnTRW5ITVJ?
BHT-101	NVnsToNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXIfGtKSzVyPUGwMlcyPzdizszN	NWLMVJhXW0GQR1XS
VMRC-RCZ	NH;ERnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLkTWM2OD1zMT6zNlAyKM7:TR?=	MlmyV2FPT0WU
ACHN	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTFzLkSyNVEh\|ryP	Ml\WV2FPT0WU
NCI-H526	M2rF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;0TWM2OD1zMT61NFQ{KM7:TR?=	M{S2bHNCVkeHUh?=
MN-60	Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDkTWM2OD1zMT61N\|kh\|ryP	MofhV2FPT0WU
NCI-H2291	NFu2cG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fyZmlEPTB;MUGuOVQ3PiEQvF2=	M1jFU3NCVkeHUh?=
SCC-25	NH3adpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFzLke1OVYh\|ryP	NVG1XHNXW0GQR1XS
SK-MEL-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPrTWM2OD1zMT63OlM4KM7:TR?=	M1;XNnNCVkeHUh?=
SN12C	NGDMZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTFzLkmzOVUh\|ryP	NIfZe5JUSU6JRWK=
NCI-H69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTF{LkSyN\|Qh\|ryP	NHnocWxUSU6JRWK=
ME-180	NVTIcJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XQ[mlEPTB;MUKuO\|A2PCEQvF2=	NIrHXFNUSU6JRWK=
MC-IXC	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTF{Lke1NVgh\|ryP	M1TDXXNCVkeHUh?=
NCI-H2347	M2PkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF{Lke2NVQh\|ryP	M4n2b3NCVkeHUh?=
M059J	M4PaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTJTWM2OD1zMj63O\|I4KM7:TR?=	M3nKbXNCVkeHUh?=
A2058	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLEU\|dMUUN3ME2xNk45PjhzIN88US=>	MoHDV2FPT0WU
VA-ES-BJ	NHzONZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLtWnhKSzVyPUGyMlg4QDVizszN	NGDONHRUSU6JRWK=
Ca9-22	NYLifXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PQVWlEPTB;MUKuPVQ2OSEQvF2=	NH[4NIZUSU6JRWK=
KNS-42	NXfxcVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfGUYZKSzVyPUGyMlk6QDRizszN	MXTTRW5ITVJ?
LoVo	M2LLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DsNWlEPTB;MUOuNlMyOyEQvF2=	M2\5OXNCVkeHUh?=
AM-38	NW\ZSpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTF\|LkK1OlYh\|ryP	NGXTXpZUSU6JRWK=
NB5	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX6bpVKSzVyPUGzMlM4PTJizszN	NGTnXY5USU6JRWK=
L-363	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TVbWlEPTB;MUOuOFA{OyEQvF2=	NWD6eWpFW0GQR1XS
SK-MEL-30	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELSfohKSzVyPUG0MlA3PDVizszN	M3HuenNCVkeHUh?=
NCI-H1563	NXnaZo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfDTWM2OD1zND62NFM6KM7:TR?=	MWXTRW5ITVJ?
NCI-H2228	M3TISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvlO3hLUUN3ME2xOE43ODd5IN88US=>	MlPEV2FPT0WU
MFM-223	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTF3LkG4NVMh\|ryP	NYiwZWp7W0GQR1XS
LB831-BLC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTF3LkK3Olch\|ryP	NYTCWJFPW0GQR1XS
SW872	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTF3LkOwPFYh\|ryP	M3PUcXNCVkeHUh?=
NCI-H522	NELBOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTF3LkOzNFYh\|ryP	MoXrV2FPT0WU
EW-1	NGfU[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17q[mlEPTB;MUWuOVQ3OiEQvF2=	Moi2V2FPT0WU
HN	NVK5cXRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTF3LkW5OFIh\|ryP	NIO3cZRUSU6JRWK=
SW837	M1G5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPHNYdOUUN3ME2xOU44QDR5IN88US=>	NHH2[4RUSU6JRWK=
SCC-9	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vRR2lEPTB;MUWuPFEyPCEQvF2=	MYrTRW5ITVJ?
MKN7	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3i1NmlEPTB;MUWuPVc{OiEQvF2=	MXHTRW5ITVJ?
KYSE-410	M3z0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PKfmlEPTB;MU[uOVkyKM7:TR?=	MXPTRW5ITVJ?
SK-N-DZ	M4DrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\NTWM2OD1zNj62NVE3KM7:TR?=	NGO2TmJUSU6JRWK=
COR-L105	Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7N[Iw{UUN3ME2xOk43PTJ6IN88US=>	M2WySXNCVkeHUh?=
LB2518-MEL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmj1TWM2OD1zNj64N\|g6KM7:TR?=	NWj3fFcyW0GQR1XS
OVCAR-4	NF:3elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTJTWM2OD1zNj64PFYzKM7:TR?=	M2TuNHNCVkeHUh?=
TK10	M4D4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTlTYtJUUN3ME2xOk46PDd\|IN88US=>	NYHiOXY6W0GQR1XS
KNS-62	NX;vbFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT1TWM2OD1zNj65O\|c4KM7:TR?=	Mn;pV2FPT0WU
RPMI-8866	NGr2SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37wWmlEPTB;MUeuNVc{OiEQvF2=	NGHxTnVUSU6JRWK=
HuP-T4	NUPIfG5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTF5LkK0PVUh\|ryP	MljkV2FPT0WU
CGTH-W-1	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXRTWM2OD1zNz61NlE6KM7:TR?=	MUDTRW5ITVJ?
T-24	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTF5LkWzOFch\|ryP	M33DcXNCVkeHUh?=
HT-3	NEjleGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTiUYlKSzVyPUG3MlU6OTRizszN	M1H5R3NCVkeHUh?=
KS-1	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTF5Lk[3N{DPxE1?	NYWzTmN5W0GQR1XS
NCI-H1792	NGTRWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrjdXlMUUN3ME2xO{44QThizszN	MV3TRW5ITVJ?
ABC-1	NFXCdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTF5LkixOFEh\|ryP	NUnPc3I6W0GQR1XS
BPH-1	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jrdWlEPTB;MUiuNVY5PSEQvF2=	NUH5T3FMW0GQR1XS
A431	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vlPGlEPTB;MUiuOFEzPyEQvF2=	MkLDV2FPT0WU
T98G	NHe5XXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTF6LkWxOVch\|ryP	NXL6OZc5W0GQR1XS
BHY	M1zVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LjOmlEPTB;MUiuPFY6KM7:TR?=	NUjYdJFoW0GQR1XS
Capan-2	NVnSdGFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXQZWNKSzVyPUG4MlkxPzhizszN	NIHp[WdUSU6JRWK=
MDA-MB-175-VII	NIftR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPld2tKSzVyPUG4MlkzODlizszN	MnzPV2FPT0WU
CAL-27	M2PyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1S3eWlEPTB;MUmuNFQ5PyEQvF2=	NFXrXYZUSU6JRWK=
AsPC-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGf6WXpKSzVyPUG5Mlg3PTdizszN	MUjTRW5ITVJ?
KU812	M3ixNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzNZWI1UUN3ME2xPU46PTd\|IN88US=>	NEnCSVBUSU6JRWK=
NCI-H441	NVf4dHh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7xNWZ4UUN3ME2yNE4xODFizszN	MlHmV2FPT0WU
Mewo	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV62R45jUUN3ME2yNE4yOjh6IN88US=>	NVr2S\|A6W0GQR1XS
SK-MEL-24	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzYSGxKSzVyPUKwMlE1PzdizszN	NHvnTmdUSU6JRWK=
NCI-H727	NWDJUJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37z[mlEPTB;MkCuNlcxPCEQvF2=	MljkV2FPT0WU
EKVX	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;xPWlEPTB;MkCuOlA3KM7:TR?=	MorCV2FPT0WU
RT-112	NUT4OogzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4S2bWlEPTB;MkCuOlEzOiEQvF2=	MYTTRW5ITVJ?
CAMA-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PUSGlEPTB;MkCuPVgxOyEQvF2=	MkDnV2FPT0WU
SW900	NEWzcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvUc2t[UUN3ME2yNU4xOTR7IN88US=>	M1;ISnNCVkeHUh?=
NCI-H23	NYi5XYlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPQT3FKSzVyPUKxMlEzPzdizszN	MWDTRW5ITVJ?
SK-PN-DW	NXPkNFBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17YOmlEPTB;MkGuNVY1QSEQvF2=	MUDTRW5ITVJ?
BB30-HNC	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrGNZdKSzVyPUKxMlI4PDVizszN	M1LHeHNCVkeHUh?=
VM-CUB-1	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTJzLkO1N\|Yh\|ryP	M4DabHNCVkeHUh?=
IST-MEL1	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTBTWM2OD1{MT6zOlkzKM7:TR?=	MYrTRW5ITVJ?
CTB-1	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJzLkS3OVUh\|ryP	MWLTRW5ITVJ?
LCLC-103H	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJ{LkG1PFIh\|ryP	NE[4VYJUSU6JRWK=
PANC-03-27	NXPkcYNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTyN2x3UUN3ME2yNk42OTZ7IN88US=>	M4nMdnNCVkeHUh?=
HTC-C3	NFHmOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\KW5FiUUN3ME2yNk42PTV3IN88US=>	MnTRV2FPT0WU
TE-8	NWjCXItkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXDd3NmUUN3ME2yN{4zPTZ3IN88US=>	NYDOTlBEW0GQR1XS
NCI-H292	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NICwUZBKSzVyPUK1MlM2OzZizszN	Mme2V2FPT0WU
COLO-680N	NY\PSohtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrteZlKSzVyPUK1MlY{OjlizszN	NYnqXGdqW0GQR1XS
KYSE-520	NHPWcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJ3Lk[0OEDPxE1?	NIq1XGZUSU6JRWK=
NB10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HoNGlEPTB;Mk[uN\|EyPyEQvF2=	NEHM[YlUSU6JRWK=
NCI-H661	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDCT5FKSzVyPUK2MlQ4OTNizszN	MXHTRW5ITVJ?
GMS-10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGru[VZKSzVyPUK2Mlg3OzhizszN	M{DzRnNCVkeHUh?=
NCI-H2122	NYf3NFhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HDb2lEPTB;Mk[uPVk6QCEQvF2=	NFP1RmNUSU6JRWK=
OVCAR-8	NWL4T4J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXZeY5KUUN3ME2yO{4xPjN6IN88US=>	M13Wc3NCVkeHUh?=
DJM-1	NWi1Xok4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37Ye2lEPTB;MkeuNVQ2PCEQvF2=	NXroTJhXW0GQR1XS
UACC-893	M3fVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJ5Lkm4O\|gh\|ryP	M363WHNCVkeHUh?=
C8166	NWXU[XVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorvTWM2OD1{OD62PVM5KM7:TR?=	Mk\3V2FPT0WU
NCI-H1693	NGT0[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTJ6Lk[5O\|Uh\|ryP	NIfzSmhUSU6JRWK=
TYK-nu	NUXsRpRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTmTWM2OD1\|MD6wN\|Q2KM7:TR?=	M3rBNXNCVkeHUh?=
SW1710	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnTOZpKSzVyPUOwMlEzPiEQvF2=	NFTTRm9USU6JRWK=
A375	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3qyTWlEPTB;M{CuN\|I1OyEQvF2=	NHL4No9USU6JRWK=
HMV-II	NGD0WGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjCWo52UUN3ME2zNU4{PTl{IN88US=>	M2H4OnNCVkeHUh?=
NCI-H2087	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LBV2lEPTB;M{GuOlM2OiEQvF2=	MX;TRW5ITVJ?
CAL-54	NXHWcVd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFu1fpFKSzVyPUOxMlczPDFizszN	M{HUWHNCVkeHUh?=
HCC70	M2DST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIixSnFKSzVyPUOyMlE{QDdizszN	M3\NcHNCVkeHUh?=
ES1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvlTWM2OD1\|Mj6zNFYzKM7:TR?=	Mn3nV2FPT0WU
NCI-H1355	NFPZSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfPZ\|ZWUUN3ME2zN{4zODRizszN	NYf0[lRkW0GQR1XS
CFPAC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILYUW9KSzVyPUOzMlI{OzJizszN	NIfJN5NUSU6JRWK=
MKN28	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHhTWM2OD1\|Mz6zPFA6KM7:TR?=	NV7GNVJTW0GQR1XS
HDLM-2	NHPjS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P4fGlEPTB;M{OuOlk{OSEQvF2=	MoDVV2FPT0WU
PANC-10-05	NWjUSJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\GTWM2OD1\|ND6xNFE1KM7:TR?=	MXrTRW5ITVJ?
SAS	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkC1TWM2OD1\|ND60OVY2KM7:TR?=	MX3TRW5ITVJ?
HCC1395	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrBWmhlUUN3ME2zOE44OTh4IN88US=>	M4e1S3NCVkeHUh?=
8305C	NEmwVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zHeGlEPTB;M{WuPFQyPSEQvF2=	NHr0TYpUSU6JRWK=
KM12	NWXGc2Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETZNXJKSzVyPUO2Mlc2PDdizszN	NH;4fY1USU6JRWK=
SW1116	NHr1b5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nHXmlEPTB;M{euOVk6OiEQvF2=	NE\aSY1USU6JRWK=
SK-MEL-1	M4W5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTN6LkOzPFkh\|ryP	NFPKOHdUSU6JRWK=
HCC2218	NX;6dHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTN6Lk[1NVkh\|ryP	M2e1W3NCVkeHUh?=
T84	NHnCd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTN6Lke0NFkh\|ryP	M1;2V3NCVkeHUh?=
ETK-1	NHHIeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGG0ZpdKSzVyPUO5MlAzOiEQvF2=	M{TlWHNCVkeHUh?=
COLO-800	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTN7LkO4Olgh\|ryP	NF;KW5NUSU6JRWK=
CAL-12T	NFPX[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTN7LkWyPFEh\|ryP	NYL6e49mW0GQR1XS
ACN	NF23bVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTRyLkS5NVEh\|ryP	NUjtRWNLW0GQR1XS
SJSA-1	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkiyTWM2OD12MT6xOVk3KM7:TR?=	NILqV5ZUSU6JRWK=
PSN1	NVHNRnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTRzLkG3OFkh\|ryP	NVmwOVBGW0GQR1XS
D-566MG	NIrCSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrlVFJRUUN3ME20NU4zODh4IN88US=>	M4H0T3NCVkeHUh?=
EGI-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq4ToFsUUN3ME20Nk41OjhizszN	MkPEV2FPT0WU
A204	NHr3OXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTDbph{UUN3ME20Nk43Ozh6IN88US=>	MoPBV2FPT0WU
Saos-2	NVXafJZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPvU4xoUUN3ME20Nk45OzZ7IN88US=>	NVfBd\|BbW0GQR1XS
SNU-C2B	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTR\|Lk[4O\|gh\|ryP	NXLLT3lWW0GQR1XS
HLE	M1voOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTR2LkC4OVYh\|ryP	MmDsV2FPT0WU
SW1463	NEG0cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTR2Lkm5O\|Eh\|ryP	NVv1UWlPW0GQR1XS
DSH1	MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTR3LkCwN\|Mh\|ryP	MWTTRW5ITVJ?
MCF7	NYnJV5JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DxTGlEPTB;NEWuOVA2OSEQvF2=	MmjZV2FPT0WU
K5	NWnPRnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnITWM2OD12NT65OFA2KM7:TR?=	Mon1V2FPT0WU
NCI-H358	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGT3PYdKSzVyPUS3MlIyPSEQvF2=	M1\LfnNCVkeHUh?=
NCI-H2030	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEX5PIFKSzVyPUS3MlI{PzRizszN	MUTTRW5ITVJ?
SW948	NVXKeVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLocZBKSzVyPUS3MlQ3PCEQvF2=	MV\TRW5ITVJ?
BALL-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\0SpJKSzVyPUS3MlYyPjhizszN	MYjTRW5ITVJ?
TE-9	NUH3VoFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTR5Lkm1PFEh\|ryP	NE[yUZZUSU6JRWK=
SK-N-FI	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHFR3VFUUN3ME20PE4xOzV6IN88US=>	M2PWVHNCVkeHUh?=
KALS-1	NGPpRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LPO2lEPTB;NEiuNVI5QSEQvF2=	NYrZNYNPW0GQR1XS
HO-1-N-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLZV4J7UUN3ME20PE44PDR3IN88US=>	NYKwS2psW0GQR1XS
NCI-H2452	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoewTWM2OD12OT6xNVUzKM7:TR?=	NW\QboFSW0GQR1XS
OC-314	NEjOV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVW2So9oUUN3ME20PU43QDN2IN88US=>	NVqwXHpDW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

体内研究

用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验： ^[1]	- 合并 Cell lines: SCLC 细胞系 Concentrations: 0-1 μM Incubation Time: 48小时 Method: 人类肿瘤细胞系在37^oC 含5% CO₂环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠 Formulation: ABT-263在10% 乙醇, 30% 聚乙二醇400, 及60% Phosal 50 PG中制成 Dosages: 100 mg/kg/d Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Navitoclax (ABT-263) SDF

分子量	974.61
化学式	C₄₇H₅₅ClF₃N₅O₆S₃
CAS号	923564-51-6
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.T790M\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Malignant Solid Neoplasm\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2
NCT00887757	Completed	Drug: ABT-263\|Drug: gemcitabine	Solid Tumors	AbbVie\|Genentech Inc.	September 2009	Phase 1
NCT00888108	Completed	Drug: ABT-263\|Drug: Docetaxel	Solid Tumor	Abbott\|Genentech Inc.	July 2009	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
回答：
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
问题 2：
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
回答：
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
最新的Bcl-2家族激活剂

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
经典的Bcl-2抑制剂

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

研究领域

产品类型

Navitoclax (ABT-263)

客户使用Selleck生产的Navitoclax (ABT-263)发表文献158篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Navitoclax (ABT-263) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品